Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Parathyroid Disease Treatment Industry By The Forecast Year 2029?
The parathyroid disease treatment market size has shown significant expansion in recent years. This market is expected to increase from $2.21 billion in 2024 to $2.37 billion in 2025, progressing at a compound annual growth rate (CAGR) of 7.2%. The growth observed during the past period can be attributed to factors such as the increasing prevalence of chronic kidney disease, a rise in osteoporosis cases, growing awareness about endocrine disorders, the expansion of diagnostic capabilities, and improving access to specialty healthcare.
The parathyroid disease treatment market is projected to experience substantial expansion in the coming years. By 2029, its valuation is anticipated to reach $3.10 billion, exhibiting a compound annual growth rate (CAGR) of 7.0%. Several factors are expected to drive this expansion during the forecast period, including an expanding elderly demographic, the wider adoption of non-surgical therapeutic approaches, a rise in postmenopausal bone disorder cases, governmental efforts supporting rare disease management, and the increasing uptake of minimally invasive parathyroidectomy procedures. Key developments anticipated in this period encompass a move towards individualized hormone treatments, the creation of prolonged-release hormone analogs, the incorporation of artificial intelligence into endocrine diagnostic processes, an emphasis on medications targeting calcium-sensing receptors, and ongoing improvements in parathyroid hormone analogs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp
What Are The Main Drivers Boosting The Parathyroid Disease Treatment Industry’s Expansion?
The increasing incidence of chronic kidney disease (CKD) is expected to fuel the expansion of the parathyroid disease treatment market. Chronic kidney disease is a long-term condition where the kidneys gradually lose functionality, leading to imbalances in minerals like calcium and phosphorus. The escalating prevalence of CKD is primarily attributed to the rising occurrence of diabetes, as sustained high blood sugar levels can progressively damage the kidneys’ filtering units, resulting in diabetic nephropathy. Parathyroid disease treatment plays a crucial role in managing chronic kidney disease (CKD) by addressing secondary hyperparathyroidism, a frequent complication in advanced CKD that disrupts calcium and phosphorus balance, contributes to bone deterioration, and promotes vascular calcification. For instance, in June 2024, figures from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and by 6.2% in 2022. Additionally, in 2022 alone, CKD accounted for around 22,000 deaths, representing 11% of all deaths in Australia, with a mortality rate of 84 per 100,000 population. Therefore, the growing prevalence of chronic kidney disease is stimulating the growth of the parathyroid disease treatment market.
What Are The Segment Types Shaping The Parathyroid Disease Treatment Market?
The parathyroid disease treatment market covered in this report is segmented –
1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid
3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin
4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)
5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions
Which Market Trends Are Creating New Opportunities In The Parathyroid Disease Treatment Industry?
Major companies in the parathyroid disease treatment market are focusing on developing innovative products like parathyroid hormone prodrugs to enhance calcium regulation and reduce dosing frequency for patients with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that transform into active PTH within the body to maintain calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a biopharmaceutical company from Denmark, gained US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), which is a prodrug of parathyroid hormone (PTH[1-34]) designed for managing chronic hypoparathyroidism in adults. This once-daily therapy delivers continuous parathyroid hormone exposure over 24 hours, presenting an alternative to standard calcium and vitamin D supplementation by directly addressing the core hormone deficiency. The approval of YORVIPATH emphasizes the rising importance of advanced hormone replacement therapies aimed at improving treatment adherence and achieving better clinical results for individuals with parathyroid disorders.
Which Leading Players Are Enhancing Their Parathyroid Disease Treatment Market Presence Worldwide?
Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Teijin Pharma Limited, Kyowa Kirin Co. Ltd., Shandong Buchang Pharmaceuticals Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., STERIS Healthcare Private Limited (subsidiary of STERIS plc), Crinetics Pharmaceuticals Inc., Amorphical Ltd., Vidasym Inc., Extend Biosciences Inc., Rani Therapeutics LLC, Pathalys Pharma Inc., ProLynx LLC.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report
How Is Parathyroid Disease Treatment Market Demand Varying Across Different Regions?
Asia-Pacific was the largest region in the parathyroid disease treatment market in 2024. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Parathyroid Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25866&type=smp
Browse Through More Reports Similar to the Global Parathyroid Disease Treatment Market 2025, By The Business Research Company
Transthyretin Amyloidosis Treatment Global Market Report 2025
Anti Thyroid Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report
Thyroid Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model